• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Italian Journal of Medicine >New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis
【24h】

New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis

机译：新的抗凝血药物对心房颤动的华法林：经济评估和成本效益分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Health care resources available for medical procedures, including pharmaceuticals, are limited worldwide. Health economic evidence is now accepted as an essential component of health technology appraisal, realizing the importance of value for money considerations for a more efficient (cost-effective) prescribing. Regulatory agencies in more and more countries perform economic evaluation and cost-effectiveness analysis in order to decide about reimbursement of a new and almost always more expensive drug. Pharmacoeconomy is now acknowledged as a science. Cost-effective analysis is just one of its approaches, measuring cost in money and benefit in terms of Quality Adjusted Life Year, a new outcome measure which combines quantity/quality of additional life-years gained with the new drug/technology. A growing body of pharmacoeconomic evidence about new anticoagulant drugs (dabigatran, rivaroxaban, apixaban) for stroke prevention in atrial fibrillation is now available. Most of this evidence comes from the National Institute of Health and Clinical Excellence (NICE) in the United Kingdom, the most referenced regulatory agency in the world. Compared to current standard therapies (warfarin), dabigatran, rivaroxaban and apixaban are cost-effective treatments for the whole population of patients with atrial fibrillation, independently of poor/good international normalized ratio control (time in therapeutic range) and risk stratification for stroke (CHADS2 score). Significant innovation and the lower rate of intracranial hemorrhage/hemorrhagic stroke coupled with the new drugs are the key drivers of these results.
机译：可用于医疗程序的医疗资源，包括药品，全球有限。卫生经济证据现在被认为是健康技术评估的重要组成部分，从而实现资金考虑的重要性，以获得更有效的（成本效益）的处方。监管机构越来越多的国家进行经济评估和成本效益分析，以决定偿还新的，几乎总是更昂贵的药物。药剂经济学现已被视为一种科学。经济高效的分析只是其方法之一，衡量资金成本和在质量调整后的终身年度的效益，新的结果措施结合了新药物/技术获得的额外寿命的数量/质量。现在，现在可以获得有关新抗凝药物（Dabigatran，Rivaroxaban，Apixaban）在心房颤动中的卒中预防的繁殖体系的身体。这些证据中的大部分证据来自于美国在英国的国家卫生和临床卓越卓越（尼斯），是世界上最引用的监管机构。与目前的标准疗法（Warfarin），Dabigatran，Rivaroxaban和Apixaban对心房颤动的患者的整个人口具有成本效益，独立于贫困/良好的国际归一化比例控制（治疗范围的时间）和中风的风险分层（ Chads2得分）。与新药物相结合的显着创新和颅内出血/出血性卒中的较低率是这些结果的关键驱动因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号